Columbia Science Review
  • Home
  • About
    • Executive Board
    • Editorial Board
  • Blog
  • Events
    • 2022-2023
    • 2021-2022
    • 2020-2021
    • 2019-2020
    • 2018-2019
    • 2017-2018
    • 2016-2017
  • Publications
  • COVID-19 Public Hub
    • Interviews >
      • Biology of COVID-19
      • Public Health
      • Technology & Data
    • Frontline Stories >
      • Healthcare Workers
      • Global Health
      • Volunteer Efforts
    • Resources & Links >
      • FAQ's
      • Resource Hubs
      • Student Opportunities
      • Podcasts & Graphics
      • Mental Health Resources
      • Twitter Feeds
      • BLM Resources
    • Columbia Events >
      • Campus Events
      • CUMC COVID-19 Symposium
      • CSR Events
    • Our Team
  • Contact

Antidepressant Potential in Magic Mushrooms

10/31/2022

0 Comments

 
Picture
Picture
Image via: Alexander Volvo, Getty Images/iStockphoto
Picture
By Jianna Martinez

​For many people with depression, standard antidepressants have become the only viable treatment option. However, antidepressants are not always effective at treating depression, especially in the long-term. A study by Northwestern University reported that more than half of people on antidepressants, here being SSRI’S, don’t get the relief they need, with 33% experiencing a return of depressive symptoms after taking this medication for a long time. The study highlighted that developers of standard depressants believed that depression is caused by stress or trauma. Therefore, the medication was developed to target aspects of the brain affected by stress or trauma instead of targeting the underlying source of depression among neurons.

This dissatisfying solution  has left the question of whether there are other substances that could have more relieving effects than the most commonly used antidepressants today. Psilocybin, a compound in mushrooms, most commonly used recreationally for its psychedelic effects, has been studied for its potential antidepressant properties, despite its classification as an illicit substance. Specifically, one of psilocybin’s compounds called COMP 360, is known to have an ability to bind to parts of the brain that are affected by depression. COMP 360 is classified as a serotonin 2A receptor type, meaning that this compound can bind to these receptors where serotonin would typically be lacking in people with depression. Research has shown that it can also increase integration between different parts of the brain. Since one of the depression’s major effects is to segregate areas of the brain,  psilocybin might present a better long-term solution to depression than antidepressants such as SSRI’s. In studies that have given patients a two-dose treatment of 25 milligrams of psilocybin and followed up with them for up to 12 months after the initial treatment, 75% of the patients reported a continued antidepressant response. These patients had previously taken antidepressants, which required continual, repeated intake that failed to produce immediate effects, contrasting psilocybin’s potential effects. Because of psilocybin’s ability to facilitate integration among the brain, it has also reportedly been effective at treating other disorders such as anxiety, PTSD and addiction.

Psilocybin’s potential to act as an antidepressant has been studied significantly; however, as research is still relatively new, certain aspects are still unknown, preventing its widespread use as of now. Trials are still underway, alongside other drugs, such as ketamine and MDMA, to study their potential in serving as antidepressants. Despite the controversies that might arise as a result of the rising use of illicit drugs as antidepressants, it is important to note that these substances can present new possibilities for improvement when moderately and safely used. Although hesitation of use is legitimate with drugs such as those that are known to be recreationally abused, challenging the notion that these substances are solely harmful is important in maximizing opportunities for those who have yet to find success among substances that are, on the other hand, socially accepted and widely accessible. 

0 Comments



Leave a Reply.

    Categories

    All
    Artificial Intelligence
    Halloween 2022
    Winter 2022-2023

    Archives

    February 2023
    November 2022
    October 2022
    June 2022
    January 2022
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    November 2019
    October 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    April 2018
    March 2018
    February 2018
    November 2017
    October 2017
    May 2017
    April 2017
    April 2016
    March 2016
    February 2016
    December 2015
    November 2015
    October 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    May 2014
    April 2014
    March 2014
    February 2014
    December 2013
    November 2013
    October 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    April 2011
    March 2011
    February 2011
    September 2010
    August 2010
    July 2010
    June 2010
    May 2010
    April 2010
    March 2010
    February 2010
    January 2010
    December 2009
    November 2009
    July 2009
    May 2009

Columbia Science Review
© COPYRIGHT 2022. ALL RIGHTS RESERVED.
Photos used under Creative Commons from driver Photographer, BrevisPhotography, digitalbob8, Rennett Stowe, Kristine Paulus
  • Home
  • About
    • Executive Board
    • Editorial Board
  • Blog
  • Events
    • 2022-2023
    • 2021-2022
    • 2020-2021
    • 2019-2020
    • 2018-2019
    • 2017-2018
    • 2016-2017
  • Publications
  • COVID-19 Public Hub
    • Interviews >
      • Biology of COVID-19
      • Public Health
      • Technology & Data
    • Frontline Stories >
      • Healthcare Workers
      • Global Health
      • Volunteer Efforts
    • Resources & Links >
      • FAQ's
      • Resource Hubs
      • Student Opportunities
      • Podcasts & Graphics
      • Mental Health Resources
      • Twitter Feeds
      • BLM Resources
    • Columbia Events >
      • Campus Events
      • CUMC COVID-19 Symposium
      • CSR Events
    • Our Team
  • Contact